Medchemexpress

Network Version

AZD-8055 Data Sheet

Product Name: AZD-8055
CAS No.: 1009298-09-2
Cat. No.: HY-10422
MWt: 465.54
Formula: C25H31N5O4
Purity : >98%
Solubility: DMSO : 33.33 mg/mL (71.59 mM; Need ultrasonic)
Mechanisms: Target: Cancer
Biological Activity:
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2[1]. IC50 & Target: IC50: 0.8 nM (mTOR)[1] In Vitro: The inhibitory activity of AZD-8055 (AZD8055) against mTOR is evaluated using two different assays. Using the truncated recombinant mTOR enzyme, the IC50 for AZD8055 is 0.13±0.05 nM. Using native mTOR enzyme complexes extracted from HeLa cells, the IC50 is 0.8±0.2 nM. AZD-8055 shows excellent selectivity (~1,000-fold) against all class I PI3K isoforms and other members of the PI3K-like kinase family. AZD-8055 inhibits the phosphorylation of mTORC1 substrates p70S6K and 4E-BP1 as well as phosphorylation of the mTORC2 substrate AKT and downstream proteins. The cellular IC50s for AZD8055 are calculated as 24±9 nM (n=13) for pAKT Ser473 and 27±3 nM (n=12) for pS6 Ser235/236 in MDA-MB-468 cells[1]. In Vivo: In mice bearing U87-MG (PTEN null) glioblastoma xenografts, oral treatment with AZD-8055 (AZD8055) results in a dose-dependent tumor growth inhibition of 33%, 48%, and 77% with 2.5, 5, and 10 mg/kg/d twice daily, respectively. A similar dose dependency is observed in nude mice bearing A549 xenografts: tumor growth inhibition is 44%, 55%, and 93% after 2.5, 5, and 10 mg/kg/d twice daily, respectively. AZD8055 also results in significant inhibition of tumor growth and/or regression in breast, lung, colon, prostate, and uterine xenograft models when administered either twice daily at 10 mg/kg or daily at a dose of 20 mg/kg[1]. AZD8055 markedly decreases the phosphorylation levels of mTOR and its substrates and the activation of microglia in vivo, and promotes the microglial polarization from M1 phenotype to M2 phenotype. In addition, administration of AZD8055 following subarachnoid hemorrhage (SAH) significantly ameliorates EBI, including neuronal apoptosis, neuronal necrosis, brain edema and blood-brain barrier permeability[2].

Caution: Not fully tested. For research purposes only

Medchemexpress LLC

www.medchemexpress.com

1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com

Keywords: buy AZD-8055 | AZD-8055 Supplier | purchase AZD-8055 | AZD-8055 cost | AZD-8055 manufacturer | order AZD-8055 | AZD-8055 distributor | AZD-8055 structure buy 1009298-09-2 | 1009298-09-2 Supplier | purchase 1009298-09-2 | 1009298-09-2 cost | 1009298-09-2 manufacturer | order 1009298-09-2 | 1009298-09-2 distributor | 1009298-09-2 structure